-- Announces Key Leadership Promotions
ALBANY, New York, Feb. 12, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI)
today announced that it has implemented several changes to further
optimize global business operations in order to enhance continuity
from early development through to commercial supply and accelerate
the company's global growth objectives.
The realigned structure will continue to improve performance and
reliability by maximizing the value of AMRI's various integrated
services for customers. Enhancing the link between operations and
core business segments, together with the corporate-level support
functions, will foster real-time decision making, appropriate
resource prioritization and integration necessary to create a more
adaptive, efficient and customer-centric global pharmaceutical
services company.
Steven R. Hagen, Ph.D., Senior
Vice President of Manufacturing and Pharmaceuticals, has assumed
oversight of AMRI's global operations infrastructure
ensuring that the manufacturing and development operations execute
efficiently, safely and to AMRI's quality standards. With this
change, AMRI has improved line-of-sight of all global operations
across all of its service offerings and all of its locations.
George Svokos, Senior Vice
President Sales and General Manager-API, has assumed responsibility
for a newly created Commercial function as Chief Commercial
Officer, which comprises Sales and Marketing, Project Management
and Supply Chain under one roof. In addition to leading the
Commercial function, Mr. Svokos will continue to spearhead AMRI's
integrated API Manufacturing offering that includes Chemical
Development and Large Scale API Manufacturing.
William S. Marth, AMRI's
president and chief executive officer, said, "We are committed to
continually improving our business operations, and are confident
that streamlining our global operations will further enhance our
ability to provide customers with a fluid, continuous supply chain
across all of our businesses. In addition, the optimization and
globalization of customer relations and project management
strengthens our ability to manage the customer interface."
In tandem with the realignment, AMRI also announced the
following senior management promotions:
Milton Boyer was promoted to
Senior Vice President of Drug Product Manufacturing, from his
former role as VP of Parenterals. Mr. Boyer's expertise from OsoBio
will be applied across all phases of Drug Product, which spans from
Pre-Formulation and Formulation Development all the way through to
Late Phase and Commercial Parenteral Manufacturing.
Christopher Conway was promoted
to Senior Vice President of Global Sales and Marketing, and is
responsible for all global sales, marketing and customer operations
functions. Mr. Conway, who joined AMRI in 2008, was most recently
Vice President of Global Sales and Marketing. Before joining AMRI,
Mr. Conway held sales and leadership positions of increasing
responsibility at Johnson and
Johnson.
To effectively support the growing interface between Chemical
Development and API and best align AMRI's resources to effectively
manage and transition customer projects, Rajesh Shenoy, Ph.D., was promoted to Senior
Director of Global Chemical Development. Dr. Shenoy has been with
AMRI since 1998 in various roles of increasing responsibility. Most
recently, Dr. Shenoy was Senior Director of Global Project
Management. Dr. Shenoy earned a Ph.D. in Organic Chemistry at the
University of Akron and conducted
postdoctoral research at Kent State
University.
About AMRI
Albany Molecular Research Inc. (AMRI) is a
global contract research and manufacturing organization that has
been working with the Life Sciences industry to improve patient
outcomes and the quality of life for more than two decades. With
locations in North America,
Europe and Asia, our key business segments include
Discovery and Development Services (DDS), Active Pharmaceutical
Ingredients (API) and Drug Product Manufacturing. Our DDS segment
provides comprehensive services from hit identification to IND,
including expertise with diverse chemistry, library design and
synthesis, in vitro biology and pharmacology, drug
metabolism and pharmacokinetics, as well as natural products. API
Manufacturing supports the chemical development and cGMP
manufacture of complex API, including potent, controlled
substances, biologics, peptides, steroids and cytotoxic compounds.
Drug Product Manufacturing supports drug product development
through commercial scale production of complex liquid-filled and
lyophilized parenteral formulations. For more information about
AMRI, please visit our website at www.amriglobal.com or follow us
on Twitter (@amriglobal).